Dual-Action-Only Proteolysis Targeting Chimeras

­PRODUCT OPPORTUNITIES

• Targeted protein degradation platform
• Precision therapeutics

PRODUCT OPPORTUNITIES

COMPETITIVE ADVANTAGES

• Selectivity
• Reduced off-target toxicity
• Platform versatility and compatibly with established PROTAC approaches

TECHNOLOGY DESCRIPTION

This invention demonstrates an AND-logic gated Proteolysis targeting chemira (PROTAC) called Dual-Action-Only PROTAC (DAO-PROTAC), where the PROTAC remains inactive until activated in presence of two orthogonal stimuli. This enables safer and more precise therapies for cancer and other diseases characterized by unique biological microenvironments.

ABOUT THE INVENTOR

Dr. Thayumanavan is a Distinguished Professor and Department Head in the Biomedical Engineering Department as well as a Distinguished Professor in the Chemistry Department at the University of Massachusetts, Amherst. His research focuses on the design, synthesis and characterization of organic macromolecules of interest in supramolecular chemistry, materials science and biological applications.

AVAILABILITY:

Available for Licensing and/or Sponsored Research

DOCKET:

UMA 25-010

PATENT STATUS:

Patent Pending

NON-CONFIDENTIAL INVENTION DISCLOSURE

LEAD INVENTOR:

Thai Thayumanavan, Ph.D.

CONTACT:

This invention demonstrates an AND-logic gated Proteolysis targeting chemira (PROTAC) called Dual-Action-Only PROTAC (DAO-PROTAC), where the PROTAC remains inactive until activated in presence of two orthogonal stimuli. This enables safer and more precise therapies for cancer and other diseases characterized by unique biological microenvironments.